Mdm2

Mouse double minute 2 homolog (MDM2) also known as E3 ubiquitin-protein ligase Mdm2 is a protein that in humans is encoded by the MDM2 gene. Mdm2 is an important negative regulator of the p53 tumor suppressor. Mdm2 protein functions both as an E3 ubiquitin ligase that recognizes the N-terminal trans-activation domain (TAD) of the p53 tumor suppressor and as an inhibitor of p53 transcriptional activation.

Cat. No.	Product name	CAS No.	Purity
T6585	SAR405838	1303607-60-4	98%
T6585	MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.
T14203	AM-8735	1429386-01-5	98%
T14203	AM-8735 is an inhibitor of MDM2 ( IC50: 25 nM).
TN4107	Ganoderic acid X	86377-53-9	98%
TN4107	Ganoderic acid X is a potential Mdm2 inhibitor(K(i) = 16nM). It is a potential anticancer drug, inhibits topoisomerases and induces apoptosis of cancer cells.
T11931	MA242	1049704-18-8	98%
T11931	MA242 is a nuclear factor of activated T cells 1 (NFAT1) for Pancreatic Cancer Therapy and dual inhibitor of murine double minute 2 (MDM2).
T12040	Milademetan	1398568-47-2	98%
T12040	Milademetan is a specific and oral inhibitor of MDM2.
T16771	RO-5963	1416663-77-8	98%
T16771	RO-5963 is a dual inhibitor of p53-MDM2 and p53-MDMX (IC50s: ~17 nM and ~24 nM, respectively).
TN1805	Isosilybin B	142796-22-3	98%
TN1805	Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway, it has anti-prostate cancer (PCA) activit...
TN4341	IVHD-valtrate	28325-56-6	98%
TN4341	VHD-valtrate has anticancer effects against human ovarian cancer cells in vitro and in vivo, it is a potential therapeutic agent for ovarian cancer, providing a ...
TQ0127	Navtemadlin	1352066-68-2	98%
TQ0127	AMG 232 is a potent, selective and orally available inhibitor of p53-MDM2 interaction (IC50: 0.6 nM). It binds to MDM2 with a Kd of 0.045 nM.
T67698	WAY-300374	350678-63-6	98%
T67698	WAY-300374 inhibits the p53-MDM2 protein-protein interaction.
T12027	MG-277	T12027	98%
T12027	MG-277 is a molecular glue compound transformed from PROTAC degradation agent, MG-277 potently inhibits tumor cell growth in a p53-independent manner.
T12031	MI-1061	1410737-34-6	98%
T12031	MI-1061 is a orally bioavailable inhibitor of MDM2 (MDM2-p53 interaction) (IC50=4.4 nM).
T9698	UC2288	1394011-91-6	98%
T9698	UC2288 is a relatively selective p21 attenuator which is synthesized based Sorafenib. UC2288 attenuates p21 protein levels with minimal effect on p21 protein sta...
T28509	RDR03871	286008-51-3	98%
T28509	RDR03871 is an MDM2 inhibitor.
T11980	MD-224	2136247-12-4	100%
T11980	MD-224 is a highly potent and efficacious MDM2 degrader based on the proteolysistargeting chimera (PROTAC) concept,and as a new class of anticancer agent.
T2243	Serdemetan	881202-45-5	98%
T2243	Serdemetan is an orally bioavailable HDM2 antagonist with potential antineoplastic activity.
T16523L	PhiKan 083	880813-36-5	98.2%
T16523L	PhiKan 083 is a carbazole derivative
T2179	Triptolide	38748-32-2	98.52%
T2179	Triptolide is a diterpenes trioxide, immunosuppressive agent extracted from the Chinese herb Tripterygium wilfordii.
T14303	Alrizomadlin	1818393-16-6	98.69%
T14303	Alrizomadlin is an orally active inhibitor of MDM2 with IC50 of 3.8 nM and Ki of 1 nM, respectively[1]. Alrizomadlin blocks the interaction of MDM2 and p53 and i...
T6614	Nutlin-3b	675576-97-3	98.83%
T6614	Nutlin-3b is a p53/MDM2 antagonist or inhibitor (IC50: 13.6 μM), 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nu...